Structure
GPCR

Structure (GPCR) earnings history

Most recent quarter

Period end
Jun 30, 2025
EPS actual
−$0.36
EPS estimate
−$0.30
EPS surprise
−21.99%
Revenue
$0.00
Reported
Aug 6, 2025

Structure Therapeutics reported Q2 2025 results on August 6, 2025, the newest quarter in the table. It posted a loss of $0.36 per share, wider than the $0.30 loss analysts expected, a miss of 21.99%. That was double the $0.18 loss in Q2 2024. The table shows no revenue figures.

The record is short: nine quarters from Q4 2022 to Q2 2025, with Q2 and Q3 2023 missing. Every quarter shown was a loss. The full year 2024 came to a loss of $0.78 per share. Losses then widened in 2025, to $0.27 in Q1 and $0.36 in Q2, for $0.63 over the first half against $0.37 a year earlier. The smallest loss in the table was $0.15 in Q4 2023. Structure beat the consensus estimate in six of the nine quarters, with the largest beat in Q4 2022 at 79.27%; the three misses include both quarters of 2025.

The only Q3 report in the table came on November 13, 2024. The table does not yet include any quarter after Q2 2025, so the next update will show whether the wider losses of early 2025 continued.

Earnings history

PeriodReportedEPS estimateEPS actualSurpriseRevenueFiling
Q2 2025Aug 6, 2025−$0.30−$0.36−21.99%$0.00SEC
Q1 2025May 8, 2025−$0.24−$0.27−11.80%$0.00SEC
Q4 2024Feb 27, 2025−$0.22−$0.21+6.42%$0.00SEC
Q3 2024Nov 13, 2024−$0.18−$0.20−9.59%$0.00SEC
Q2 2024Aug 8, 2024−$0.22−$0.18+18.18%$0.00SEC
Q1 2024May 9, 2024−$0.19−$0.19+2.21%$0.00SEC
Q4 2023Mar 8, 2024−$0.19−$0.15+19.35%$0.00SEC
Q1 2023May 11, 2023−$0.34−$0.25+27.01%$0.00SEC
Q4 2022Mar 30, 2023−$0.82−$0.17+79.27%$0.00SEC

Quarterly revenue

Q4 2022
$0.00
Q1 2023
$0.00
Q4 2023
$0.00
Q1 2024
$0.00
Q2 2024
$0.00
Q3 2024
$0.00
Q4 2024
$0.00
Q1 2025
$0.00
Q2 2025
$0.00

Frequently asked questions

  • When did Structure (GPCR) last report earnings?

    Structure last reported on Aug 6, 2025, covering fiscal Q2 2025.

  • Did GPCR beat earnings estimates?

    No. Structure reported EPS of −$0.36 for Q2 2025 against a −$0.30 estimate — a 21.99% miss.

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.